At #EHA2026, phase 3 MonumenTAL-3 showed talquetamab plus daratumumab with or without pomalidomide improved PFS in R/R MM, with higher and deeper responses and a trend toward improved OS, as discussed by Dr Peter Voorhees👉https://bit.ly/4bqFMtS #MultipleMyeloma #Hematology #Oncology
bit.ly
Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma - ecancer
Dr Peter Voorhees speaks to ecancer about results from the phase 3 MonumenTAL 3 trial evaluating talquetamab, a GPRC5D targeting bispecific antibody, in combina